World Journal of Diabetes最新文献

{"title":"Unveiling mitochondrial mysteries: Exploring novel tRNA variants in type 2 diabetes mellitus.","authors":"Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng","doi":"10.4239/wjd.v16.i1.98798","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.98798","url":null,"abstract":"<p><p>The recent study of Ding <i>et al</i> provides valuable insights into the functional implications of novel mitochondrial tRNA^Trp and tRNA^Ser(AGY) variants in type 2 diabetes mellitus (T2DM). This editorial explores their findings, highlighting the role of mitochondrial dysfunction in the pathogenesis of T2DM. By examining the molecular mechanisms through which these tRNA variants contribute to disease progression, the study introduces new targets for therapeutic strategies. We discuss the broader implications of these results, emphasizing the importance of understanding mitochondrial genetics in addressing T2DM.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"98798"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing metformin efficacy with cholecalciferol and taurine in diabetes therapy: Potential and limitations.","authors":"Gehan El-Akabawy, Nabil Eid","doi":"10.4239/wjd.v16.i1.100066","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.100066","url":null,"abstract":"<p><p>Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), poses a significant global health challenge. Traditional management strategies primarily focus on glycemic control; however, there is a growing need for comprehensive approaches addressing the complex pathophysiology of diabetes complications. The recent study by Attia <i>et al</i> explores the potential of a novel therapy combining metformin with cholecalciferol (vitamin D3) and taurine to mitigate T2DM-related complications in a rat model. The findings indicate that this treatment combination improves glycemic control and reduces oxidative stress, inflammation, and lipid abnormalities. However, the study is limited by a lack of safety profile data and in-depth molecular mechanism insights. This editorial critically highlights the study's strengths and weaknesses, compares it against other combination therapy research in T2DM, and underscores the need to explore further the mechanisms underpinning the observed therapeutic effects and investigate the safety profile of this novel approach.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"100066"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress.","authors":"Zhi-Min Lin, Han-Yuan Gao, Shu-Han Shi, Yue-Ting Li","doi":"10.4239/wjd.v16.i1.92711","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.92711","url":null,"abstract":"<p><strong>Background: </strong>Mizagliflozin (MIZ) is a specific inhibitor of sodium-glucose cotransport protein 1 (SGLT1) originally developed as a medication for diabetes.</p><p><strong>Aim: </strong>To explore the impact of MIZ on diabetic nephropathy (DN).</p><p><strong>Methods: </strong>Diabetic mice were created using db/db mice. They were administered either a low dose (0.5 mg/kg) or a high dose (1.0 mg/kg) of the SGLT1 inhibitor MIZ <i>via</i> stomach gavage for 8 weeks. Subsequently, mesangial cells (MCs) were isolated and subjected to high glucose conditions in culture to assess the effects of MIZ on DN.</p><p><strong>Results: </strong>The results showed that low doses of MIZ significantly reduced albuminuria to a level comparable to that achieved with high doses in db/db mice. High doses of MIZ led to a substantial increase in body weight in mice, along with decreased blood glucose levels and food intake. Moreover, the intervention with high-dose MIZ notably decreased the expression of extracellular matrix genes, such as collagen type 1 alpha 1 mRNA levels. While the expression of SGLT1 increased after exposure to high glucose, it decreased following treatment with MIZ. Furthermore, MIZ intervention was more effective in improving lactate dehydrogenase levels in MCs induced by high glucose compared to canagliflozin. MIZ also significantly elevated levels of antioxidant enzymes superoxide dismutase, catalase, and glutathione, while reducing malondialdehyde levels.</p><p><strong>Conclusion: </strong>These findings indicate that MIZ can ameliorate DN by inhibiting SGLT1, inflammation, and oxidative stress.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"92711"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acellular fish skin grafts in diabetic foot ulcer care: Advances and clinical insights.","authors":"Yu Zhao, Quan-Quan Shen","doi":"10.4239/wjd.v16.i1.100597","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.100597","url":null,"abstract":"<p><p>Diabetic foot ulcers (DFUs) represents a significant public health issue, with a rising global prevalence and severe potential complications including amputation. Traditional treatments often fall short due to various limitations such as high recurrence rates and extensive resource utilization. This editorial explores the innovative use of acellular fish skin grafts as a transformative approach in DFU management. Recent studies and a detailed case report highlight the efficacy of acellular fish skin grafts in accelerating wound closure, reducing dressing changes, and enhancing patient outcomes with a lower socio-economic burden. Despite their promise, challenges such as limited availability, patient acceptance, and the need for further research persist. Addressing these through more extensive randomized controlled trials and fostering a multidisciplinary treatment approach may optimize DFU care and reduce the global health burden associated with these complex wounds.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"100597"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between age at diagnosis of diabetes and ocular disease: Insights from a recent article.","authors":"Shi-Qi Liu, Dong Wang, Cheng-Chun Tang","doi":"10.4239/wjd.v16.i1.94846","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.94846","url":null,"abstract":"<p><p>In this article, we discuss Ye <i>et al</i>'s recent article on the association between age at diabetes diagnosis and subsequent risk of age-related ocular diseases. The study, which utilized United Kingdom Biobank data, highlighted a strong link between early diabetes onset and major eye conditions, such as cataracts, glaucoma, age-related macular degeneration, and vision loss, independent of glycemic control and disease duration. This finding challenges the previous belief that diabetic eye disease primarily correlates with hyperglycemia. As lifestyles evolve and the age of diabetes diagnosis decreases, understanding this relationship may reveal the complex pathogenesis underlying diabetes-related complications. This editorial summarizes potential mechanisms connecting the age of diabetes onset with four types of ocular diseases, emphasizing the significance of early diagnosis.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"94846"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspectives and the future of disease-modifying therapies in type 1 diabetes.","authors":"Sunetra Mondal, Joseph M Pappachan","doi":"10.4239/wjd.v16.i1.99496","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.99496","url":null,"abstract":"<p><p>Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen. Preclinical and clinical trials have demonstrated its efficacy in reducing the decline in serum C-peptide levels and the need for insulin therapy if used early in the disease process of T1DM. The benefits have been apparent as early as six months to as long as seven years after therapy. It has recently been approved by the Food and Drug Administration to delay the onset of clinical (stage 3) type 1 diabetes in children above 8 years of age. In their recent meta-analysis published in the <i>World Journal of Diabetes</i>, Ma <i>et al</i> found that those in the teplizumab treatment group have a greater likelihood of reduction in insulin use, change in C-peptide response, and better glycemic control compared to the control group with a good safety profile. However, all the included randomized control trials have been conducted in high-income countries. High cost of therapy and unknown utility of the molecule in stage 3 disease limit its widespread use.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"99496"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal glucagon-like peptide-1: A new regulator of impaired counterregulatory responses to hypoglycemia in type 1 diabetes mellitus.","authors":"Le-Rong Liu, Yuan-Yuan Luo, Pei-Zhu Su, Cong Zhang, Zhao-Tao Li","doi":"10.4239/wjd.v16.i1.99726","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.99726","url":null,"abstract":"<p><p>In this article, we review the study by Jin <i>et al</i>, which examined the role of intestinal glucagon-like peptide-1 (GLP-1) in counterregulatory responses to hypoglycemia in patients with type 1 diabetes mellitus (T1DM). With the global rise of T1DM, there is an increased burden on society and healthcare systems. Due to insulin therapy and islet dysfunction, T1DM patients are highly vulnerable to severe hypoglycemia, a leading cause of mortality. In healthy individuals, counterregulatory mechanisms restore blood glucose during hypoglycemia, but repeated episodes impair these responses. Jin <i>et al</i> demonstrated that overexpression of GLP-1 attenuates the sympathetic-adrenal reflex and disrupts the secretion of counterregulatory hormones such as glucagon during hypoglycemia, leading to counterregulatory dysfunction. These findings highlight the critical role of GLP-1 in the impaired counterregulatory response to hypoglycemia in T1DM patients and provide new insights into the potential application of GLP-1-related therapies in T1DM patients.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"99726"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus and glymphatic dysfunction: Roles for oxidative stress, mitochondria, circadian rhythm, artificial intelligence, and imaging.","authors":"Kenneth Maiese","doi":"10.4239/wjd.v16.i1.98948","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.98948","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a debilitating disorder that impacts all systems of the body and has been increasing in prevalence throughout the globe. DM represents a significant clinical challenge to care for individuals and prevent the onset of chronic disability and ultimately death. Underlying cellular mechanisms for the onset and development of DM are multi-factorial in origin and involve pathways associated with the production of reactive oxygen species and the generation of oxidative stress as well as the dysfunction of mitochondrial cellular organelles, programmed cell death, and circadian rhythm impairments. These pathways can ultimately involve failure in the glymphatic pathway of the brain that is linked to circadian rhythms disorders during the loss of metabolic homeostasis. New studies incorporate a number of promising techniques to examine patients with metabolic disorders that can include machine learning and artificial intelligence pathways to potentially predict the onset of metabolic dysfunction.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"98948"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes-inducing effects of bronchial asthma.","authors":"Mohammed Al-Beltagi, Adel Salah Bediwy, Nermin Kamal Saeed, Hosameldin A Bediwy, Reem Elbeltagi","doi":"10.4239/wjd.v16.i1.97954","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.97954","url":null,"abstract":"<p><strong>Background: </strong>The relationship between diabetes mellitus (DM) and asthma is complex and can impact disease trajectories.</p><p><strong>Aim: </strong>To explore the bidirectional influences between the two conditions on clinical outcomes and disease control.</p><p><strong>Methods: </strong>We systematically reviewed the literature on the relationship between DM and asthma, focusing on their impacts, mechanisms, and therapeutic implications. Various studies were assessed, which investigated the effect of glycemic control on asthma outcomes, lung function, and exacerbations. The study highlighted the role of specific diabetes medications in managing asthma.</p><p><strong>Results: </strong>The results showed that poor glycemic control in diabetes can exacerbate asthma, increase hospitalizations, and reduce lung function. Conversely, severe asthma, especially in obese individuals, can complicate diabetes management and make glycemic control more difficult. The diabetes-associated mechanisms, such as inflammation, microangiopathy, and oxidative stress, can exacerbate asthma and decrease lung function. Some diabetes medications exhibit anti-inflammatory effects that show promise in mitigating asthma exacerbations.</p><p><strong>Conclusion: </strong>The complex interrelationship between diabetes and asthma suggests bidirectional influences that affect disease course and outcomes. Inflammation and microvascular complications associated with diabetes may worsen asthma outcomes, while asthma severity, especially in obese individuals, complicates diabetes control. However, the current research has limitations, and more diverse longitudinal studies are required to establish causal relationships and identify effective treatment strategies for individuals with both conditions.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"97954"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of the glycemic background patterns and the diabetes management efficacy in poorly controlled type 2 diabetes.","authors":"Ayşe N Erbakan, Müzeyyen Arslan Bahadır, Fatoş N Kaya, Büşra Güleç, Miraç Vural Keskinler, Ümmügülsüm Aktemur Çelik, Özge Faydalıel, Banu Mesçi, Aytekin Oğuz","doi":"10.4239/wjd.v16.i1.98322","DOIUrl":"https://doi.org/10.4239/wjd.v16.i1.98322","url":null,"abstract":"<p><strong>Background: </strong>Inadequate glycemic control in patients with type 2 diabetes (T2DM) is a major public health problem and a significant risk factor for the progression of diabetic complications.</p><p><strong>Aim: </strong>To evaluate the effects of intensive and supportive glycemic management strategies over a 12-month period in individuals with T2DM with glycated hemoglobin (HbA1c) ≥ 10% and varying backgrounds of glycemic control.</p><p><strong>Methods: </strong>This prospective observational study investigated glycemic control in patients with poorly controlled T2DM over 12 months. Participants were categorized into four groups based on prior glycemic history: Newly diagnosed, previously well controlled with recent worsening, previously off-target but now worsening, and HbA1c consistently above 10%. HbA1c levels were monitored quarterly, and patients received medical, educational, and dietary support as needed. The analysis focused on the success rates of good glycemic control and the associated factors within each group.</p><p><strong>Results: </strong>The study showed significant improvements in HbA1c levels in all participants. The most significant improvement was observed in individuals newly diagnosed with diabetes: 65% achieved an HbA1c target of ≤ 7%. The results varied between participants with different glycemic control histories, followed by decreasing success rates: 39% in participants with previously good glycemic control, 21% in participants whose glycemic control had deteriorated compared to before, and only 10% in participants with persistently poor control, with mean HbA1c levels of 6.3%, 7.7%, 8.2%, and 9.7%, respectively. After one year, 65.2% of the \"newly diagnosed patients\", 39.3% in the \"previously controlled group\", 21.9% in the \"previously off-target but now worsened'\" group and 10% in the \"poorly controlled from the start\" group had achieved HbA1c levels of 7 and below.</p><p><strong>Conclusion: </strong>In poorly controlled diabetes, the rate at which treatment goals are achieved is associated with the glycemic background characteristics, emphasizing the need for tailored strategies. Therefore, different and comprehensive treatment approaches are needed for patients with persistent uncontrolled diabetes.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 1","pages":"98322"},"PeriodicalIF":4.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}